home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  June 14, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 461 active entries

Benitec Limited

Level 16, 356 Collins Street
Melbourne, Victoria, Australia 3000

Phone: +61 437211200
Fax: +61 (0) 3 98598827

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Stock symbol: ASX:BLT
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Benitec – Leader in Gene Silencing Technology

Benitec Ltd. is dedicated to developing therapeutics to treat serious diseases and advancing medical research using DNA-directed RNA interference (ddRNAi). ddRNAi is a proprietary technology developed to trigger the natural gene silencing process called RNA interference (RNAi), a precise and proven process for silencing any gene in any cell of any multicellular organism.

Benitec, a pioneer and the ddRNAi leader, was the first company to trigger RNAi in human cells and whole mammals, and holds a dominant patent estate in the rapidly expanding RNAi field. The Company has continued to expand its proprietary platform by developing a comprehensive suite of technologies to deliver the full potential of ddRNAi. Benitec’s customers and partners are international biopharmaceutical companies and research institutes. The Company is growing through strategic alliances and licensing for high value therapeutic and biomedical applications.

Benitec’s ddRNAi technology provides unique capability and significant competitive advantages for:
• Developing treatments for major diseases such as cancers, autoimmune diseases, HIV/AIDS and other chronic viral infections
• Disease modeling in vitro and in vivo
• Target validation in vitro and in vivo
• High throughput functional genomics.

Selected Categories:

Product Company   Service Company
- Research
- Agriculture
- General

Last update of this entry: October 14, 2006

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.